Eligibility Criteria

  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID and consent group of participants with or without 21-Hydroxylase deficiency and involved in the "Potential Modulatory Role of Osteoprotegerin in Bone Metabolism of Patients with 21-Hydroxylase Deficiency" project.
    3. registration: This dataset has been checked for HIPAA sensitive information, consistency between the asserted data in the study description with the data available through dbGaP, distributable study document corresponding to the dataset, format for study loading, and items that may be ambiguous to dbGaP users. Code meanings and truncated variable descriptions are provided as submitted. For questions regarding the data, please contact the study investigators.
    4. demographics: This dataset has been checked for HIPAA sensitive information, consistency between the asserted data in the study description with the data available through dbGaP, distributable study document corresponding to the dataset, format for study loading, and items that may be ambiguous to dbGaP users. Code meanings and truncated variable descriptions are provided as submitted. For questions regarding the data, please contact the study investigators.
    5. eligibilityform: This dataset has been checked for HIPAA sensitive information, consistency between the asserted data in the study description with the data available through dbGaP, distributable study document corresponding to the dataset, format for study loading, and items that may be ambiguous to dbGaP users. Code meanings and truncated variable descriptions are provided as submitted. For questions regarding the data, please contact the study investigators.
    6. intakeform: This dataset has been checked for HIPAA sensitive information, consistency between the asserted data in the study description with the data available through dbGaP, distributable study document corresponding to the dataset, format for study loading, and items that may be ambiguous to dbGaP users. Code meanings and truncated variable descriptions are provided as submitted. For questions regarding the data, please contact the study investigators.
Inclusion and exclusion criteria
Descrizione

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
*Inclusion Criteria:*
Descrizione

Elig.phs001314.v1.p1.1

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1512693
For People with 21-OHD:
Descrizione

Elig.phs001314.v1.p1.2

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1698493
UMLS CUI [1,2]
C0852654
21OHD documented by molecular genetic analysis (mutations in CYP21A2 gene on both parental alleles)
Descrizione

Elig.phs001314.v1.p1.3

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0852654
UMLS CUI [1,2]
C1513380
UMLS CUI [1,3]
C0026882
UMLS CUI [1,4]
C1413861
UMLS CUI [1,5]
C1706086
UMLS CUI [1,6]
C0030551
UMLS CUI [1,7]
C0002085
Treatment with glucocorticoid replacement since infancy (begun within the first year of life)
Descrizione

Elig.phs001314.v1.p1.4

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0744425
UMLS CUI [1,2]
C1711239
UMLS CUI [1,3]
C0231330
Available hormonal data and treatment details over the 5 years prior to study entry
Descrizione

Elig.phs001314.v1.p1.5

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0470187
UMLS CUI [1,2]
C0019932
UMLS CUI [1,3]
C1511726
UMLS CUI [1,4]
C0087111
UMLS CUI [1,5]
C1522508
UMLS CUI [1,6]
C0332152
UMLS CUI [1,7]
C0008976
UMLS CUI [1,8]
C0679823
Premenopausal
Descrizione

Elig.phs001314.v1.p1.6

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0232969
Female
Descrizione

Elig.phs001314.v1.p1.7

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0086287
Ages 20-35 years
Descrizione

Elig.phs001314.v1.p1.8

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0001779
For Healthy Controls:
Descrizione

Elig.phs001314.v1.p1.9

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1708335
No diagnosis of 21-OHD CAH, as confirmed by molecular genetic analysis
Descrizione

Elig.phs001314.v1.p1.10

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1298908
UMLS CUI [1,2]
C0011900
UMLS CUI [1,3]
C0852654
UMLS CUI [1,4]
C0750484
UMLS CUI [1,5]
C1513380
No first degree relative is enrolled as a 21-OHD CAH participant
Descrizione

Elig.phs001314.v1.p1.11

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1298908
UMLS CUI [1,2]
C1517194
UMLS CUI [1,3]
C1516879
UMLS CUI [1,4]
C0852654
UMLS CUI [1,5]
C1698493
Premenopausal
Descrizione

Elig.phs001314.v1.p1.12

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0232969
Female
Descrizione

Elig.phs001314.v1.p1.13

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0086287
Ages 20-35 years
Descrizione

Elig.phs001314.v1.p1.14

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0001779
*Exclusion Criteria:*
Descrizione

Elig.phs001314.v1.p1.15

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0680251
Medical disorder or treatment with medications known to affect bone density (other than glucocorticoids for 21-OHD CAH patients), including, but not limited to growth hormone, IGF-I, depo-medroxyprogesterone acetate, biphosphonates, oral contraceptives, androgens, thyroxine, or aromatase inhibitors
Descrizione

Elig.phs001314.v1.p1.16

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C3146298
UMLS CUI [1,3]
C0013227
UMLS CUI [1,4]
C0392760
UMLS CUI [1,5]
C0005938
UMLS CUI [2,1]
C0037663
UMLS CUI [2,2]
C0021665
UMLS CUI [2,3]
C0086129
UMLS CUI [2,4]
C0065864
UMLS CUI [2,5]
C0012544
UMLS CUI [2,6]
C0009905
UMLS CUI [2,7]
C0002844
UMLS CUI [2,8]
C0040165
UMLS CUI [2,9]
C0593802
Pregnant
Descrizione

Elig.phs001314.v1.p1.17

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0032961
Any smoking within the 6 months prior to study entry
Descrizione

Elig.phs001314.v1.p1.18

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1519386
UMLS CUI [1,2]
C0332152
UMLS CUI [1,3]
C0008976
UMLS CUI [1,4]
C0679823
Cardiac pacemaker or other implanted electronic medical device
Descrizione

Elig.phs001314.v1.p1.19

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2735362
UMLS CUI [1,2]
C0848753

Similar models

Eligibility Criteria

  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID and consent group of participants with or without 21-Hydroxylase deficiency and involved in the "Potential Modulatory Role of Osteoprotegerin in Bone Metabolism of Patients with 21-Hydroxylase Deficiency" project.
    3. registration: This dataset has been checked for HIPAA sensitive information, consistency between the asserted data in the study description with the data available through dbGaP, distributable study document corresponding to the dataset, format for study loading, and items that may be ambiguous to dbGaP users. Code meanings and truncated variable descriptions are provided as submitted. For questions regarding the data, please contact the study investigators.
    4. demographics: This dataset has been checked for HIPAA sensitive information, consistency between the asserted data in the study description with the data available through dbGaP, distributable study document corresponding to the dataset, format for study loading, and items that may be ambiguous to dbGaP users. Code meanings and truncated variable descriptions are provided as submitted. For questions regarding the data, please contact the study investigators.
    5. eligibilityform: This dataset has been checked for HIPAA sensitive information, consistency between the asserted data in the study description with the data available through dbGaP, distributable study document corresponding to the dataset, format for study loading, and items that may be ambiguous to dbGaP users. Code meanings and truncated variable descriptions are provided as submitted. For questions regarding the data, please contact the study investigators.
    6. intakeform: This dataset has been checked for HIPAA sensitive information, consistency between the asserted data in the study description with the data available through dbGaP, distributable study document corresponding to the dataset, format for study loading, and items that may be ambiguous to dbGaP users. Code meanings and truncated variable descriptions are provided as submitted. For questions regarding the data, please contact the study investigators.
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Elig.phs001314.v1.p1.1
Item
*Inclusion Criteria:*
boolean
C1512693 (UMLS CUI [1,1])
Elig.phs001314.v1.p1.2
Item
For People with 21-OHD:
boolean
C1698493 (UMLS CUI [1,1])
C0852654 (UMLS CUI [1,2])
Elig.phs001314.v1.p1.3
Item
21OHD documented by molecular genetic analysis (mutations in CYP21A2 gene on both parental alleles)
boolean
C0852654 (UMLS CUI [1,1])
C1513380 (UMLS CUI [1,2])
C0026882 (UMLS CUI [1,3])
C1413861 (UMLS CUI [1,4])
C1706086 (UMLS CUI [1,5])
C0030551 (UMLS CUI [1,6])
C0002085 (UMLS CUI [1,7])
Elig.phs001314.v1.p1.4
Item
Treatment with glucocorticoid replacement since infancy (begun within the first year of life)
boolean
C0744425 (UMLS CUI [1,1])
C1711239 (UMLS CUI [1,2])
C0231330 (UMLS CUI [1,3])
Elig.phs001314.v1.p1.5
Item
Available hormonal data and treatment details over the 5 years prior to study entry
boolean
C0470187 (UMLS CUI [1,1])
C0019932 (UMLS CUI [1,2])
C1511726 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,4])
C1522508 (UMLS CUI [1,5])
C0332152 (UMLS CUI [1,6])
C0008976 (UMLS CUI [1,7])
C0679823 (UMLS CUI [1,8])
Elig.phs001314.v1.p1.6
Item
Premenopausal
boolean
C0232969 (UMLS CUI [1,1])
Elig.phs001314.v1.p1.7
Item
Female
boolean
C0086287 (UMLS CUI [1,1])
Elig.phs001314.v1.p1.8
Item
Ages 20-35 years
boolean
C0001779 (UMLS CUI [1,1])
Elig.phs001314.v1.p1.9
Item
For Healthy Controls:
boolean
C1708335 (UMLS CUI [1,1])
Elig.phs001314.v1.p1.10
Item
No diagnosis of 21-OHD CAH, as confirmed by molecular genetic analysis
boolean
C1298908 (UMLS CUI [1,1])
C0011900 (UMLS CUI [1,2])
C0852654 (UMLS CUI [1,3])
C0750484 (UMLS CUI [1,4])
C1513380 (UMLS CUI [1,5])
Elig.phs001314.v1.p1.11
Item
No first degree relative is enrolled as a 21-OHD CAH participant
boolean
C1298908 (UMLS CUI [1,1])
C1517194 (UMLS CUI [1,2])
C1516879 (UMLS CUI [1,3])
C0852654 (UMLS CUI [1,4])
C1698493 (UMLS CUI [1,5])
Elig.phs001314.v1.p1.12
Item
Premenopausal
boolean
C0232969 (UMLS CUI [1,1])
Elig.phs001314.v1.p1.13
Item
Female
boolean
C0086287 (UMLS CUI [1,1])
Elig.phs001314.v1.p1.14
Item
Ages 20-35 years
boolean
C0001779 (UMLS CUI [1,1])
Elig.phs001314.v1.p1.15
Item
*Exclusion Criteria:*
boolean
C0680251 (UMLS CUI [1,1])
Elig.phs001314.v1.p1.16
Item
Medical disorder or treatment with medications known to affect bone density (other than glucocorticoids for 21-OHD CAH patients), including, but not limited to growth hormone, IGF-I, depo-medroxyprogesterone acetate, biphosphonates, oral contraceptives, androgens, thyroxine, or aromatase inhibitors
boolean
C0012634 (UMLS CUI [1,1])
C3146298 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
C0392760 (UMLS CUI [1,4])
C0005938 (UMLS CUI [1,5])
C0037663 (UMLS CUI [2,1])
C0021665 (UMLS CUI [2,2])
C0086129 (UMLS CUI [2,3])
C0065864 (UMLS CUI [2,4])
C0012544 (UMLS CUI [2,5])
C0009905 (UMLS CUI [2,6])
C0002844 (UMLS CUI [2,7])
C0040165 (UMLS CUI [2,8])
C0593802 (UMLS CUI [2,9])
Elig.phs001314.v1.p1.17
Item
Pregnant
boolean
C0032961 (UMLS CUI [1,1])
Elig.phs001314.v1.p1.18
Item
Any smoking within the 6 months prior to study entry
boolean
C1519386 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C0679823 (UMLS CUI [1,4])
Elig.phs001314.v1.p1.19
Item
Cardiac pacemaker or other implanted electronic medical device
boolean
C2735362 (UMLS CUI [1,1])
C0848753 (UMLS CUI [1,2])